NORTHBROOK, Ill., April 23, 2024 /PRNewswire/ -- Endevica Bio, a company developing first-in-class peptide drug candidates, announced its novel weight-loss treatment was successful in a recent diet-induced obesity (DIO) rat study.
Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics
Endevica Reports Positive TCMCB07 Data from Single Ascending Dose Portion of Phase 1 Clinical Trial in Cachexia
NORTHBROOK, Ill.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, announced the first patient in its Phase 1 study has been dosed with TCMCB07, the company’s melanocortin?4 antagonist peptide candidate for the treatment of cachexia. The study will enroll up to 97 healthy volunteers to assess the safety of TCMCB07, with data expected in the first quarter of 2023.
NORTHBROOK, Ill.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for its lead investigational product, TCMCB07, allowing the company to proceed with initiating clinical studies. TCMCB07 is an investigational melanocortin?4 antagonist peptide designed to treat cachexia in people that have cancer and other chronic diseases. Endevica Bio plans to initiate Phase 2 clinical studies in pancreatic cancer in 2Q 2023.
COLUMBIA, Mo.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, appointed Daniel Marks, M.D. Ph.D. as Chief Medical Officer (CMO). Dr. Marks is a prominent researcher in cachexia, Endevica’s first targeted indication for its lead product candidate TCMCB07, and Dr. Marks will help guide the company through pre-clinical and clinical development.
COLUMBIA, Mo.--(BUSINESS WIRE)--Researchers affiliated with Endevica Bio (formerly known as Tensive Controls Inc.), a company developing first-in-class peptide drug candidates with better safety and efficacy properties, published new data on Endevica’s lead compound, TCMCB07, in the journal ACS Pharmacology & Translational Science. The research describes the unique mechanisms and properties of the drug, specifically in the treatment of cachexia, and the potential for producing a platform for drug-like peptides based on this evidence.